메뉴 건너뛰기




Volumn 9, Issue 6, 2010, Pages 1609-1617

A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor

Author keywords

[No Author keywords available]

Indexed keywords

N [4 (1 BENZOYL 4 PIPERIDINYL)BUTYL] 3 (3 PYRIDINYL)ACRYLAMIDE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID;

EID: 77953408297     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1130     Document Type: Article
Times cited : (69)

References (36)
  • 1
    • 36949061541 scopus 로고
    • Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor
    • Goldin A, Venditti JM, Kline I, Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966;212:1548-50.
    • (1966) Nature , vol.212 , pp. 1548-1550
    • Goldin, A.1    Venditti, J.M.2    Kline, I.3    Mantel, N.4
  • 2
    • 0014608878 scopus 로고
    • Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates
    • Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 1969;48:2140-55.
    • (1969) J Clin Invest , vol.48 , pp. 2140-2155
    • Hryniuk, W.M.1    Bertino, J.R.2
  • 3
    • 0010348233 scopus 로고
    • Long-term remissions in childhood acute leukemia: Use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor
    • Phila
    • Djerassi I, Abir E, Royer GL, Treat CL. Long-term remissions in childhood acute leukemia: use of infrequent infusions of methotrexate; supportive roles of platelet transfusions and citrovorum factor. Clin Pediatr (Phila) 1966;5:502-9.
    • (1966) Clin Pediatr , vol.5 , pp. 502-509
    • Djerassi, I.1    Abir, E.2    Royer, G.L.3    Treat, C.L.4
  • 4
    • 0016242550 scopus 로고
    • Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma
    • Jaffe N, Frei E III, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7.
    • (1974) N Engl J Med , vol.291 , pp. 994-997
    • Jaffe, N.1    Frei III, E.2    Traggis, D.3    Bishop, Y.4
  • 6
    • 33846693322 scopus 로고    scopus 로고
    • The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals
    • DOI 10.1097/MOG.0b013e32801b3c8f, PII 0000157420070300000011
    • Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007;23:164-70. (Pubitemid 46192971)
    • (2007) Current Opinion in Gastroenterology , vol.23 , Issue.2 , pp. 164-170
    • Revollo, J.R.1    Grimm, A.A.2    Imai, S.-I.3
  • 7
    • 10944270187 scopus 로고    scopus 로고
    • The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells
    • DOI 10.1074/jbc.M408388200
    • Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-63. (Pubitemid 40017813)
    • (2004) Journal of Biological Chemistry , vol.279 , Issue.49 , pp. 50754-50763
    • Revollo, J.R.1    Grimm, A.A.2    Imai, S.-I.3
  • 9
    • 0242526050 scopus 로고    scopus 로고
    • FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis
    • Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003;63:7436-42. (Pubitemid 37413486)
    • (2003) Cancer Research , vol.63 , Issue.21 , pp. 7436-7442
    • Hasmann, M.1    Schemainda, I.2
  • 11
    • 0034482908 scopus 로고    scopus 로고
    • Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro
    • Hansen CM, Hansen D, Holm PK, Larsson R, Binderup L. Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro. Anticancer Res 2000;20:4211-20. (Pubitemid 32143725)
    • (2000) Anticancer Research , vol.20 , Issue.6 B , pp. 4211-4220
    • Hansen, C.M.1    Hansen, D.2    Holm, P.K.3    Larsson, R.4    Binderup, L.5
  • 12
    • 0037091007 scopus 로고    scopus 로고
    • Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells
    • DOI 10.1016/S0006-2952(02)00890-0, PII S0006295202008900
    • Lovborg H, Martinsson P, Gullbo J, Ekelund S, Nygren P, Larsson R. Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochem Pharmacol 2002;63:1491-8. (Pubitemid 34457965)
    • (2002) Biochemical Pharmacology , vol.63 , Issue.8 , pp. 1491-1498
    • Lovborg, H.1    Martinsson, P.2    Gullbo, J.3    Ekelund, S.4    Nygren, P.5    Larsson, R.6
  • 13
    • 64049094455 scopus 로고    scopus 로고
    • Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo
    • Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009;77:1612-20.
    • (2009) Biochem Pharmacol , vol.77 , pp. 1612-1620
    • Formentini, L.1    Moroni, F.2    Chiarugi, A.3
  • 14
    • 33847711354 scopus 로고    scopus 로고
    • Hypoxia signalling controls metabolic demand
    • DOI 10.1016/j.ceb.2007.02.003, PII S0955067407000178
    • Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007;19:223-9. (Pubitemid 46386401)
    • (2007) Current Opinion in Cell Biology , vol.19 , Issue.2 , pp. 223-229
    • Brahimi-Horn, M.C.1    Chiche, J.2    Pouyssegur, J.3
  • 15
    • 0000459772 scopus 로고
    • Ûber den Stoffwechsel der Tumoren
    • Warburg O, Posener K, Negelein E. Ûber den Stoffwechsel der Tumoren. Biochem Z 1924;152:319-44.
    • (1924) Biochem Z , vol.152 , pp. 319-344
    • Warburg, O.1    Posener, K.2    Negelein, E.3
  • 16
    • 38149105811 scopus 로고    scopus 로고
    • The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    • Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008;26:45-51.
    • (2008) Invest New Drugs , vol.26 , pp. 45-51
    • Holen, K.1    Saltz, L.B.2    Hollywood, E.3    Burk, K.4    Hanauske, A.R.5
  • 17
    • 14844291424 scopus 로고    scopus 로고
    • Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study
    • DOI 10.1016/j.ejca.2004.12.023
    • Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41:702-7. (Pubitemid 40342552)
    • (2005) European Journal of Cancer , vol.41 , Issue.5 , pp. 702-707
    • Ravaud, A.1    Cerny, T.2    Terret, C.3    Wanders, J.4    Bui, B.N.5    Hess, D.6    Droz, J.-P.7    Fumoleau, P.8    Twelves, C.9
  • 18
    • 77953419543 scopus 로고    scopus 로고
    • A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion
    • ASCO
    • Pishvaian M, Marshall J, Hwang J, et al. A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. 2009 ASCO Annual Meeting. ASCO; 2009.
    • (2009) 2009 ASCO Annual Meeting
    • Pishvaian, M.1    Marshall, J.2    Hwang, J.3
  • 19
    • 77953411487 scopus 로고    scopus 로고
    • Use of vitamin PP compounds
    • inventors; PCT patent WO 99/53920. 21.04
    • Biedermann E, Hasmann M, Löser R, et al., inventors; Use of vitamin PP compounds. PCT patent WO 99/53920. 1999 21.04.
    • (1999)
    • Biedermann, E.1    Hasmann, M.2    Löser, R.3
  • 20
    • 40849119972 scopus 로고    scopus 로고
    • NAD+ and vitamin B3: From metabolism to therapies
    • Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther 2008;324:883-93.
    • (2008) J Pharmacol Exp Ther , vol.324 , pp. 883-893
    • Sauve, A.A.1
  • 21
    • 34548329953 scopus 로고    scopus 로고
    • Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells
    • DOI 10.1074/jbc.M610357200
    • Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007;282:24574-82. (Pubitemid 47347525)
    • (2007) Journal of Biological Chemistry , vol.282 , Issue.34 , pp. 24574-24582
    • Hara, N.1    Yamada, K.2    Shibata, T.3    Osago, H.4    Hashimoto, T.5    Tsuchiya, M.6
  • 22
    • 62149150332 scopus 로고    scopus 로고
    • Niacin status, NAD distribution and ADP-ribose metabolism
    • Kirkland JB. Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des 2009;15:3-11.
    • (2009) Curr Pharm des , vol.15 , pp. 3-11
    • Kirkland, J.B.1
  • 23
    • 34447335060 scopus 로고    scopus 로고
    • Niacin in cardiovascular prevention: Mechanisms, efficacy, and safety
    • Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415-20.
    • (2007) Curr Opin Lipidol , vol.18 , pp. 415-420
    • Guyton, J.R.1
  • 24
    • 40349094705 scopus 로고    scopus 로고
    • Nicotinic acid: An old drug with a promising future
    • DOI 10.1038/sj.bjp.0707528, PII 0707528
    • Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153 Suppl 1:S68-75. (Pubitemid 351340990)
    • (2008) British Journal of Pharmacology , vol.153 , Issue.SUPPL. 1
    • Bodor, E.T.1    Offermanns, S.2
  • 25
    • 66449134807 scopus 로고    scopus 로고
    • Niacin status and treatment-related leukemogenesis
    • Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther 2009;8:725-32.
    • (2009) Mol Cancer Ther , vol.8 , pp. 725-732
    • Kirkland, J.B.1
  • 29
    • 0022379935 scopus 로고
    • Characterization of three new variant type cell lines derived from small cell carcinoma of the lung
    • de Leij L, Postmus PE, Buys CH, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985;45:6024-33.
    • (1985) Cancer Res , vol.45 , pp. 6024-6033
    • De Leij, L.1    Postmus, P.E.2    Buys, C.H.3
  • 31
    • 0242317675 scopus 로고    scopus 로고
    • Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis
    • Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003;31:e73.
    • (2003) Nucleic Acids Res , vol.31
    • Peirson, S.N.1    Butler, J.N.2    Foster, R.G.3
  • 33
    • 67650318141 scopus 로고    scopus 로고
    • Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
    • Beauparlant P, Bedard D, Bernier C, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009;20:346-54.
    • (2009) Anticancer Drugs , vol.20 , pp. 346-354
    • Beauparlant, P.1    Bedard, D.2    Bernier, C.3
  • 35
    • 1842689677 scopus 로고    scopus 로고
    • Inhibition of human P450 enzymes by nicotinic acid and nicotinamide
    • DOI 10.1016/j.bbrc.2004.03.137, PII S0006291X0400645X
    • Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun 2004;317:950-6. (Pubitemid 38481464)
    • (2004) Biochemical and Biophysical Research Communications , vol.317 , Issue.3 , pp. 950-956
    • Gaudineau, C.E.1    Auclair, K.2
  • 36
    • 70350538957 scopus 로고    scopus 로고
    • The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in NAPRT1-deficient tumors
    • Watson M, Roulston A, Belec L, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in NAPRT1-deficient tumors. Mol Cell Biol 2009;29:5872-88.
    • (2009) Mol Cell Biol , vol.29 , pp. 5872-5888
    • Watson, M.1    Roulston, A.2    Belec, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.